The International Association for the Study of Lung Cancer (IASLC)
Lung Cancer Staging Project, Data Elements v1.13, 10JAN2021

Contents
1.1 Registration ........................................................................................................................................... 2
1.2 Patient Characteristics .......................................................................................................................... 3
1.3 Laboratory Values at Diagnosis ......................................................................................................... 5
1.4 Lung Cancer with Multiple Lesions ..................................................................................................... 8
1.5 Primary Tumour Description ............................................................................................................... 9
1.6 Pre-Treatments TNM Tests ................................................................................................................ 12
1.7 Treatments ........................................................................................................................................... 13
1.8 T-Descriptors, by Pre-Treatment/Evaluative Findings ..................................................................... 16
1.9 Pre-Treatment/Evaluative N Category ............................................................................................... 18
1.10 M-Descriptors, by Pre-Treatment/Evaluative Findings .................................................................. 21
1.11 T-Descriptors, by Post-Surgical Pathological Findings .................................................................. 24
1.12 Post Surgical/Pathologic N Category ............................................................................................... 28
1.13 M-Descriptors, After Attempted Resection of the Primary Tumour ............................................. 31
1.14 Systemic Treatments and Radiotherapy ......................................................................................... 34
1.15 Follow-up ........................................................................................................................................... 36
1.16 Progression/Recurrence ...................................................................................................................... 37
1.17 Genetic Biomarkers ............................................................................................................................ 38
1.18 Copy Number Alteration (CAN) Biomarkers ................................................................................... 42
1.19 Protein Alterations ............................................................................................................................. 45
In accordance with the Data Use Agreement for the project, personal identifiers such as name, initials, medical record number, etc. must not be included in the Patient Code.

Patients included in the 9th Edition staging project must be newly diagnosed lung cancer patients, with a diagnosis date no earlier than January 1, 2011 and no later than December 31, 2019.
1.2 Patient Characteristics

- **Subject ID:** 20210001
- **Site Number:** University of Michigan
- **Principal Investigator:** Smith, John
- **Patient Code:** UM046-13

**IMPORTANT:** This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

**TABS: Patient**

- **Smoking history:**
- **If a former smoker, number of years since quitting:**
- **Number of years smoked:**
- **Average number of packs per day:**
- **Weight loss in previous six months:**
- **Zubrod Performance Status:**

- **Height:** cm
- **Weight:** kg

**Comorbidity** [hyperlink to definitions with citation]

- **Tobacco consumption:**
- **Diabetes mellitus:**
- **Renal insufficiency:**
- **Respiratory comorbidity:**
- **Cardiovascular comorbidity:**

- **Previously treated malignancy (other than basal cell skin carcinoma and in situ carcinoma of the cervix):**
- **Alcoholism:**

[Submit] [Cancel] eCRF Version: 1.0
**Form Question:** Smoking History

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never smoked</td>
</tr>
<tr>
<td>Former smoker</td>
</tr>
<tr>
<td>Current smoker</td>
</tr>
<tr>
<td>No Data</td>
</tr>
</tbody>
</table>

**Form Question:** Weight loss in the previous six months

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 5% of body weight</td>
</tr>
<tr>
<td>&gt;= 5% - 10% of body weight</td>
</tr>
<tr>
<td>&gt;= 10% of body weight</td>
</tr>
<tr>
<td>No Data</td>
</tr>
</tbody>
</table>

**Form Question:** Zubrod Performance Status

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – Fully active</td>
</tr>
<tr>
<td>1 – Restricted</td>
</tr>
<tr>
<td>2 – No work, ambulatory</td>
</tr>
<tr>
<td>3 – Limited self-care</td>
</tr>
<tr>
<td>4 – Completely disabled</td>
</tr>
<tr>
<td>No Data</td>
</tr>
</tbody>
</table>

**Form Question:** Comorbidity options from ‘Diabetes mellitus’ to ‘Alcoholism’

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>No Data</td>
</tr>
</tbody>
</table>
1.3 Laboratory Values at Diagnosis

**Subject ID:** 3001.001

**Site Number:** University of Michigan

**Principal Investigator:** Smroh, John

**Patient Code:** UMIM016.13

**IMPORTANT:** This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

**TAB: Patient**

**What was the lab specimen collection date?**

**Gender:** Male

**Age:** 23

Please select an existing lab, or create one by using the shaded box below.

**Lab Name plus any qualifiers (ex. effective dates, patient sex, age ranges):**

**Create New Lab**

**Lab Name plus any qualifiers (ex. effective dates, patient sex, age ranges):**

**Copy values from an existing lab:**

**No; create blank set**

**Create Lab**

Complete the following data items. Enter or update limits of normal values and lab units as necessary. The lab data will be updated upon form submission.

<table>
<thead>
<tr>
<th>Not Done</th>
<th>Result</th>
<th>Lab Lower Limit of Normal</th>
<th>Lab Upper Limit of Normal</th>
<th>Lab Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium Level:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkaline Phosphatase:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium, NA:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White Cell Count:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleophil Count:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet Count:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute Lymphocyte Count:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PET Standardized Uptake Value (SUV):**

**Maximum SUV Primary Tumour:**

**Maximum SUV Nodes:**

**Maximum SUV (nodes) applies to**

**Pulmonary Function Test:**

**Forced Vital Capacity (FVC):** liter % Predicted FVC: %

**Forced Expiratory Volume in 1 Second (FEV1):** liter % Predicted FEV1: %

**Date of trial entry if database is from a clinical trial:**

**Submit**

**Cancel**
**Form Question:** Lab Units – LDH

Field size: (NUMBER 6,2)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ukat/L</td>
</tr>
<tr>
<td>IU/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Hemoglobin;

Field size: (NUMBER 6,2)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/dL</td>
</tr>
<tr>
<td>mmol/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Calcium Level

Field size: (NUMBER 4,2)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmol/L</td>
</tr>
<tr>
<td>mg/dl</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Alkaline Phosphatase

Field size: (NUMBER 6,2)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ukat/L</td>
</tr>
<tr>
<td>IU/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Sodium, NA

Field size: (NUMBER 3)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmol/L</td>
</tr>
</tbody>
</table>
**Form Question:** Lab Units – White Cell Count

Field size: (NUMBER 8,3)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10^9 \times$ cells/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Neutrophil Count

Field size: (NUMBER 8,3)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10^9 \times$ cells/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Platelet Count

Field size: (NUMBER 9,3)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10^9 \times$ cells/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Absolute Lymphocyte Count

Field size: (NUMBER 8,3)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10^9 \times$ cells/L</td>
</tr>
</tbody>
</table>

**Form Question:** Lab Units – Albumin

Field size for Result, Lab Lower Limit of Normal and Lab Upper Limit of Normal: (NUMBER 3,1)

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/L</td>
</tr>
<tr>
<td>g/dL</td>
</tr>
</tbody>
</table>

**Form Question:** Maximum SUV applies to

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hilar/interlobar nodes</td>
</tr>
<tr>
<td>Mediastinal nodes</td>
</tr>
<tr>
<td>SuprACLavicular nodes</td>
</tr>
</tbody>
</table>
1.4 Lung Cancer with Multiple Lesions

Form Question: Are there multiple malignant lung lesions?

| Display Value | Yes | No |
## 1.5 Primary Tumour Description

Subject ID: 20010001  
Site Number: University of Michigan  
Principal Investigator: Smith, John  
Patient Code: UMD45.13

**IMPORTANT:** This form has a 10 minute timeout period. You can click on the form at any time to reset your timeout period.

**TUMOUR: 1**  
**TAB: Primary Tumour**

**Instructions:** For patients undergoing resection, use final description of tumour (post-resection) to complete this form.

**Method of detection:**

- [ ] Cytology
- [ ] Histology

**Date of histology or cytology obtained:**

- [ ] DD-MM-YYYY

Please specify the location of primary tumour. Do not include the locations of the involved nodes or additional nodules. Select all that apply.

- [ ] Right Main Bronchus
- [ ] Right Upper Lobe
- [ ] Right Middle Lobe
- [ ] Right Lower Lobe
- [ ] Right Upper Lobar Bronchus
- [ ] Right Middle Lobar Bronchus
- [ ] Intermediate Bronchus
- [ ] Right Lower Lobar Bronchus
- [ ] Main Bronchus, Side Not Specified
- [ ] Trachea
- [ ] Canna
- [ ] Left Main Bronchus
- [ ] Left Upper Lobe
- [ ] Left Lower Lobe
- [ ] Left Upper Lobar Bronchus
- [ ] Left Lower Lobar Bronchus

**Differentiation grade:**

- [ ]

**Histologic Type, WHO 2016 edition:**

- [ ]

**Paraneoplastic syndrome:**

- [ ]

**Pleural Effusion:**

- [ ]

[Submit] [Cancel]  
eCRF Version: 1.0
Form Question: Method of detection

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
</tr>
<tr>
<td>Screening</td>
</tr>
<tr>
<td>Incidental</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

Form Question: Differentiation grade

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gx: Cannot be assessed</td>
</tr>
<tr>
<td>G1: Well differentiated</td>
</tr>
<tr>
<td>G2: Moderately differentiated</td>
</tr>
<tr>
<td>G3: Poorly differentiated</td>
</tr>
<tr>
<td>G4: Undifferentiated</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

Form Question: Histologic type, WHO 2015 edition

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenocarcinoma, noninvasive: Adenocarcinoma in situ</td>
</tr>
<tr>
<td>Adenocarcinoma: Minimally invasive adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, Invasive: Lepidic adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, Invasive: Acinar adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, Invasive: Papillary adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, Invasive: Micropapillary adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, Invasive: Solid adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, Invasive: Invasive mucinous adenocarcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma, NOS</td>
</tr>
<tr>
<td>Squamous cell carcinoma: Squamous cell carcinoma in situ</td>
</tr>
<tr>
<td>Squamous cell carcinoma: Invasive squamous cell carcinoma</td>
</tr>
<tr>
<td>Neuroendocrine tumor: Diffuse idiopathic pulmonary neuroendocrine cell</td>
</tr>
<tr>
<td>Neuroendocrine tumor: Small cell carcinoma</td>
</tr>
<tr>
<td>Neuroendocrine tumor: Large cell neuroendocrine carcinoma</td>
</tr>
<tr>
<td>Carcinoid tumor: typical carcinoid</td>
</tr>
<tr>
<td>Carcinoid tumor: atypical carcinoid</td>
</tr>
<tr>
<td>Large cell carcinoma</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
</tr>
<tr>
<td>Sarcomatoid carcinomas: Pleomorphic carcinoma</td>
</tr>
<tr>
<td>Sarcomatoid carcinomas: Giant cell carcinoma</td>
</tr>
<tr>
<td>Sarcomatoid carcinoma: Carcinosarcoma</td>
</tr>
<tr>
<td>Salivary gland type tumors: Mucoepidermoid carcinoma</td>
</tr>
<tr>
<td>Salivary gland type tumors: Adenoid cystic carcinoma</td>
</tr>
<tr>
<td>Non Small Cell Lung Cancer – Not otherwise specified</td>
</tr>
<tr>
<td>Combined small cell carcinoma and nonsmall cell carcinoma</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Not lung cancer</td>
</tr>
</tbody>
</table>

**Form Question:** Paraneoplastic syndrome

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>No Data</td>
</tr>
</tbody>
</table>

**Form Question:** Pleural Effusion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present – cytology positive</td>
</tr>
<tr>
<td>Present – cytology negative</td>
</tr>
<tr>
<td>Present – cytology unknown</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>
1.6 Pre-Treatments TNM Tests

<table>
<thead>
<tr>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td>Standard radiology (e.g. chest x-ray)</td>
<td>CT of chest/upper abdomen</td>
</tr>
<tr>
<td>CT of the brain</td>
<td>MRI of chest/upper abdomen</td>
<td>MRI of the brain</td>
</tr>
<tr>
<td>Bone Scan</td>
<td>PET or PET-CT</td>
<td>Percutaneous needle biopsy or cytology</td>
</tr>
<tr>
<td>Bronchoscopy with or without ultrasonograph (EBUS), with biopsy or cytology</td>
<td>Gastroscopy with or without ultrasonograph (EUS), with biopsy or cytology</td>
<td>Mediastinoscopy with biopsy or cytology</td>
</tr>
<tr>
<td>Mediastinoscopy or extended cervical mediastinoscopy</td>
<td>Transcervical lymphadenectomy</td>
<td>Thorascopic biopsy or cytology</td>
</tr>
<tr>
<td>Laparoscopy</td>
<td>Diagnostic thoracotomy</td>
<td>Video mediastinoscopy</td>
</tr>
<tr>
<td>Video-assisted mediastinal lymphadenectomy (VAMLA)</td>
<td>Transcervical extended mediastinal lymphadenectomy (TEMLA)</td>
<td></td>
</tr>
<tr>
<td>Data not available</td>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

If "Other", specify: [blank]

Submit Cancel

eCRF Version: 1.1
1.7 Treatments
**Form Question:** Was the removal of the primary tumour attempted?

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

**Form Question:** Extent of resection

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thoracotomy, no resection</td>
</tr>
<tr>
<td>Resection of the airway without removal of lung parenchyma</td>
</tr>
<tr>
<td>Resection of the airway with removal of lung parenchyma</td>
</tr>
<tr>
<td>Endoscopic resection</td>
</tr>
<tr>
<td>Segmentectomy</td>
</tr>
<tr>
<td>Wedge resection</td>
</tr>
<tr>
<td>Lobectomy</td>
</tr>
<tr>
<td>Bilobectomy</td>
</tr>
<tr>
<td>Pneumonectomy</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

**Form Question:** Status of resection margin

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative free margins</td>
</tr>
<tr>
<td>Microscopic residual disease</td>
</tr>
<tr>
<td>Macroscopic residual disease</td>
</tr>
</tbody>
</table>

**Form Question:** Completeness of resection

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>R0</td>
</tr>
<tr>
<td>R1</td>
</tr>
<tr>
<td>R2</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>
**Form Question:** Systemic therapy

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Systemic therapy</td>
</tr>
<tr>
<td>Systemic therapy, no resection attempt</td>
</tr>
<tr>
<td>Systemic therapy before resection, no systemic therapy after resection (or no data on systemic therapy after resection)</td>
</tr>
<tr>
<td>Systemic therapy after attempted resection</td>
</tr>
<tr>
<td>Systemic therapy before and after attempted resection</td>
</tr>
<tr>
<td>Attempted resection, sequence of systemic therapy unknown (or no data on systemic therapy after resection)</td>
</tr>
</tbody>
</table>

**Form Question:** Immunotherapy

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Immunotherapy</td>
</tr>
<tr>
<td>Immunotherapy, no resection attempt</td>
</tr>
<tr>
<td>Immunotherapy before resection, no immunotherapy after resection (or no data on immunotherapy after resection)</td>
</tr>
<tr>
<td>Immunotherapy after attempted resection</td>
</tr>
<tr>
<td>Immunotherapy before and after attempted resection</td>
</tr>
<tr>
<td>Attempted resection, sequence of immunotherapy unknown (or no data on immunotherapy after resection)</td>
</tr>
</tbody>
</table>

**Form Question:** Radiation administered to thorax

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No radiation therapy</td>
</tr>
<tr>
<td>Radiation therapy, no resection attempt: standard or stereotactic</td>
</tr>
<tr>
<td>Radiation therapy before resection, no radiation therapy after resection (or no data on radiation therapy after resection)</td>
</tr>
<tr>
<td>Radiation therapy after attempted resection</td>
</tr>
<tr>
<td>Radiation therapy before and after attempted resection</td>
</tr>
<tr>
<td>Attempted resection, sequence of radiation therapy unknown (or no data on radiation therapy after resection)</td>
</tr>
</tbody>
</table>
1.8 T-Descriptors, by Pre-Treatment/Evaluative Findings

Subject ID: 20010001
Site Number: University of Michigan
Principal Investigator: Smith, John
Patient Code: UM046-13

IMPORTANT: This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

**TUMOUR: 1**

**TAB: Primary Tumour**

**Location of primary tumour (with highest T-category):** (Refer to Primary Tumour Description form where V3.TN = 1)

**Instructions:** Indicate T-category. (Click here for the 8th edition criteria)

**Lung tumour T Category:** [ ]

**Size of primary tumour (solid component), or pre-treatment/evaluative findings:** [ ] cm, largest dimension

(For AIS or SCIS tumours classified as in situ prior to [or without] resection, enter zero in the box above. AIS=adenocarcinoma in situ, SCIS=squamous cell carcinoma in situ)

Is this a part-solid tumour with a GGO/lepidic component? [ ] Yes [ ] No

If "Yes", please also state (combined solid and part-solid component together): [ ] cm, longest dimension

**Lymphangiitis present?** [ ] Yes [ ] No

Specify all locations of lymphangiitis, if present:
- [ ] Adjacent to primary
- [ ] Elsewhere in lobe
- [ ] In other bilateral lobes
- [ ] Contralateral lung

**Instructions: T-Descriptors. Check ALL that apply, regardless of final T-category:**

- Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy (T0)
- No evidence of primary tumour (T0)
- Carcinoma in situ (Tis)
- Minimally invasive adenocarcinoma (T1a)
- Tumour 2 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus) (T1)
- Superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus (T1)
- Involves main bronchus regardless of distance to the carina, but without involving the carina (T2)
- Involves visceral pleura (T2)
- Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, either involving part of the lung or the entire lung (T2)
- Partial pleural invasion (PL2) (T2)
- Chest wall invasion (T3)
- Apical chest wall invasion, stellate ganglion, inferior branches of the brachial plexus (below C6) (T3)
- Phrenic nerve involvement (T3)
- Parasternal pericardium involvement (T3)
- Associated separate tumour node(s) in the same lobe as the primary (T3)

**Histology of separate node(s) confirmed?** [ ]
### Form Question: Lung tumour T Category

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
</tr>
<tr>
<td>Tis</td>
</tr>
<tr>
<td>T1mi</td>
</tr>
<tr>
<td>T1a</td>
</tr>
<tr>
<td>T1b</td>
</tr>
<tr>
<td>T1c</td>
</tr>
<tr>
<td>T2a</td>
</tr>
<tr>
<td>T2b</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T4</td>
</tr>
</tbody>
</table>

### Form Question: Histology of separate nodules confirmed?

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>
1.9 Pre-Treatment/Evaluative N Category

<table>
<thead>
<tr>
<th>N Category</th>
<th>Set all stations to &quot;x&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supraclavicular</td>
<td></td>
</tr>
<tr>
<td>#1R</td>
<td>#1L</td>
</tr>
<tr>
<td>Upper paratracheal</td>
<td></td>
</tr>
<tr>
<td>#2R</td>
<td>#2L</td>
</tr>
<tr>
<td>Pre-vascular</td>
<td></td>
</tr>
<tr>
<td>#3R</td>
<td>#3aL</td>
</tr>
<tr>
<td>Retrotracheal</td>
<td></td>
</tr>
<tr>
<td>#3p</td>
<td></td>
</tr>
<tr>
<td>Lower paratracheal</td>
<td></td>
</tr>
<tr>
<td>#4R</td>
<td>#4L</td>
</tr>
<tr>
<td>Sub-aortic</td>
<td></td>
</tr>
<tr>
<td>#5</td>
<td></td>
</tr>
<tr>
<td>Para-aortic</td>
<td></td>
</tr>
<tr>
<td>#6</td>
<td></td>
</tr>
<tr>
<td>Subcarinal</td>
<td></td>
</tr>
<tr>
<td>#7</td>
<td></td>
</tr>
<tr>
<td>Paraoesophageal</td>
<td></td>
</tr>
<tr>
<td>#8R</td>
<td>#8L</td>
</tr>
</tbody>
</table>
### Pulmonary ligament

<table>
<thead>
<tr>
<th>#9L:</th>
<th>#9R:</th>
</tr>
</thead>
</table>

### Hilar

<table>
<thead>
<tr>
<th>#10L:</th>
<th>#10R:</th>
</tr>
</thead>
</table>

### Interlobar

<table>
<thead>
<tr>
<th>#11L:</th>
<th>#11R:</th>
</tr>
</thead>
</table>

### Lobal

<table>
<thead>
<tr>
<th>#12L:</th>
<th>#12R:</th>
</tr>
</thead>
</table>

### Segmental

<table>
<thead>
<tr>
<th>#13L:</th>
<th>#13R:</th>
</tr>
</thead>
</table>

### Subsegmental

<table>
<thead>
<tr>
<th>#14L:</th>
<th>#14R:</th>
</tr>
</thead>
</table>

**Size of largest node:** [cm]

**Method of measurement:** [ ]

**Extracapsular involvement?** [ ]

- If Yes, N3 extracapsular involvement: [ ]
- If Yes, N2 extracapsular involvement: [ ]
- If Yes, N1 extracapsular involvement: [ ]

**Number of N3 nodes explored:** [ ]  **Number of positive N3 nodes:** [ ]

**Number of N2 nodes explored:** [ ]  **Number of positive N2 nodes:** [ ]

**Number of N1 nodes explored:** [ ]  **Number of positive N1 nodes:** [ ]
Form Question: N Category

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N0</td>
</tr>
<tr>
<td>N1</td>
</tr>
<tr>
<td>N2</td>
</tr>
<tr>
<td>N3</td>
</tr>
<tr>
<td>NX</td>
</tr>
</tbody>
</table>

Form Question: All staging questions before ‘Size of largest node’

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
</tr>
<tr>
<td>-</td>
</tr>
<tr>
<td>ND</td>
</tr>
</tbody>
</table>

Form Question: Method of measurement

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-ray</td>
</tr>
<tr>
<td>CT</td>
</tr>
<tr>
<td>Ultrasound</td>
</tr>
<tr>
<td>Biopsy</td>
</tr>
</tbody>
</table>

Form Question: Extracapsular involvement?

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

Form Question: N3 extracapsular involvement; N2 extracapsular involvement; N1 extracapsular involvement

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>
1.10 M-Descriptors, by Pre-Treatment/Evaluative Findings

<table>
<thead>
<tr>
<th>Subject ID: 00010001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Number: University of Michigan</td>
</tr>
<tr>
<td>Principal Investigator: Smith, John</td>
</tr>
<tr>
<td>Patient Code: UM045-13</td>
</tr>
</tbody>
</table>

**IMPORTANT:** This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

**Instructions: Indicate M-category. [Click here for 8th edition criteria]**

- **M Category by pre-treatment/evaluative findings:**
- **Was cytologic or histologic evidence obtained for M1 Disease?:**
- **Pleural metastases:**
- **Pericardial nodules:**
- **Pleural effusion:**
- **Pericardial effusion:**

If a pleural effusion was detected but not aspirated, please select one of the following reasons:
- Aspiration not needed; evidence of benignity (e.g. improvement without anti-cancer treatments)
- Aspiration not needed; evidence of other metastatic disease (M1b, M1c)
- Unable to be aspirated; alternative etiology clinically likely (e.g. pleuropneumonic, heart failure)
- Unable to be aspirated; clinically likely malignant
- Other reason

**Central or hilar lymph nodes:**

**Are there any distant (extrathoracic) metastases?:**

<table>
<thead>
<tr>
<th>Sites of distant metastases</th>
<th>Presence/Number of Lesions</th>
<th>If multiple lesions, specify number of lesions</th>
<th>Size of largest lesion (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal lymph nodes:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other distant lymph nodes:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peritoneum:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenal:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[Submit] [Cancel] eCRF Version: 1.0
Form Question: M status by pre-treatment/evaluative finding

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
</tr>
<tr>
<td>M1a</td>
</tr>
<tr>
<td>M1b</td>
</tr>
<tr>
<td>M1c</td>
</tr>
</tbody>
</table>

Form Question: Was cytologic or histologic evidence obtained for M1 Disease?; Are there any distant (extrathoracic) metastases?

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

Form Question: Pleural nodules; Pleural effusion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
</tr>
<tr>
<td>Ipsilateral</td>
</tr>
<tr>
<td>Contralateral</td>
</tr>
<tr>
<td>Bilateral</td>
</tr>
<tr>
<td>Present, side not specified</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

Form Question: Pericardial nodules; Pericardial effusion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

Form Question: Cytology

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
</tr>
<tr>
<td>Negative</td>
</tr>
<tr>
<td>Not done</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>
Form **Question:** If pleural effusion was detected but not aspirated

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspiration not needed; evidence of benignity (e.g. improvement without anti-cancer treatments)</td>
</tr>
<tr>
<td>Aspiration not needed; evidence of other metastatic disease (M1b, M1c)</td>
</tr>
<tr>
<td>Unable to be aspirated; alternative etiology clinically likely (e.g. parapneumonic, heart failure)</td>
</tr>
<tr>
<td>Unable to be aspirated; clinically likely malignant</td>
</tr>
<tr>
<td>Other reason</td>
</tr>
</tbody>
</table>

Form **Question:** Sites of distant metastases

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single lesion</td>
</tr>
<tr>
<td>Multiple lesions</td>
</tr>
<tr>
<td>Present, number of lesion not specified</td>
</tr>
<tr>
<td>Absent</td>
</tr>
</tbody>
</table>
1.11 T-Descriptors, by Post-Surgical Pathological Findings

Subject ID: 20010001
Site Number: University of Michigan
Principle Investigator: Smith, John
Patient Code: UN1045-13

IMPORTANT: This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

TUMOUR: 1

T classification: Primary Tumour

Location of primary tumour (with highest T-category):

Instructions: Indicate T-category. [Click here for 8th edition criteria]

Lung tumour T Category: [ ] by post-surgical/pathological findings

Size of primary tumour (invasive component only), by post-surgical/pathological findings: [ ] cm, longest dimension

(For squamous cell carcinoma in situ (SCCIS) or adenocarcinoma in situ (AIS), enter zero in the box above.)

Total (combined) invasive and noninvasive (lepidic) size, if applicable: [ ] cm, longest dimension

[Click here for the 8th edition criteria for coding T for subsolid nodules and measuring part-solid nodules]

Vascular invasion:

Status of the tissues:

Lymphatic, venous invasion:

Pleural invasion:

Perineural invasion:

Spread through the air spaces (STAD):

Instructions: T-Descriptors. Check ALL that apply, regardless of final T-category:

- Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy (T0)
- No evidence of primary tumour (T0)
- Carcinoma in situ (Tis)
- Malignant pleural mesothelioma (M1)
- Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the ipsilateral bronchus (i.e., not in the main bronchus) (T1)
- Superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus (T1)
- Involves main bronchus regardless of distance to the carina, but without involving the carina (T2)
- Involves visceral pleura (T2)
  - Depth of visceral pleura invasion. Click here for definitions:
    - PL0
    - PL1
    - PL2
    - Associated with stenosis or obstructive pneumonitis that extends to the hilar region, either involving part of the lung or the entire lung (T2)
- Panacinar Pleura invasion (PL3) (T3)
<table>
<thead>
<tr>
<th>Chest wall invasion (T3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axial chest wall invasion, stellate ganglion, inferior branches of the brachial plexus (below C5) (T3)</td>
</tr>
<tr>
<td>Pleural nerve involvement (T3)</td>
</tr>
<tr>
<td>Pericardial involvement (T3)</td>
</tr>
<tr>
<td>Associated separate tumour nodule(s) in the same lobe as the primary</td>
</tr>
</tbody>
</table>

**Histology of separate nodule(s) confirmed?**

<table>
<thead>
<tr>
<th>Discrepancy invasion (T4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mediastinum invasion (T4)</td>
</tr>
<tr>
<td>Heart invasion (T4)</td>
</tr>
<tr>
<td>Great vessel invasion (T4)</td>
</tr>
<tr>
<td>Superior vena cava</td>
</tr>
<tr>
<td>Inferior vena cava</td>
</tr>
<tr>
<td>Pulmonary vein</td>
</tr>
<tr>
<td>Pulmonary artery</td>
</tr>
<tr>
<td>Aorta</td>
</tr>
<tr>
<td>Main stem of pulmonary artery</td>
</tr>
</tbody>
</table>

**Histology of separate nodule(s) confirmed?**

<table>
<thead>
<tr>
<th>Tracheal invasion (T4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent laryngeal nerve invasion (T4)</td>
</tr>
<tr>
<td>Esophageal invasion (T4)</td>
</tr>
<tr>
<td>Axial chest wall invasion (T4): evidence of invasion of the vertebral body or spinal canal, encasement of the subclavian vessels, or unequivocal involvement of the superior branches of the brachial plexus (C8 or above) (T4)</td>
</tr>
<tr>
<td>Carina invasion (T4)</td>
</tr>
<tr>
<td>Separate tumour nodule(s) in a different (ipsilateral) lobe to that of the primary (T4)</td>
</tr>
</tbody>
</table>

**Histology of separate nodule(s) confirmed?**
### Form Question: Lung tumour T Category

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
</tr>
<tr>
<td>Tis</td>
</tr>
<tr>
<td>T1mi</td>
</tr>
<tr>
<td>T1a</td>
</tr>
<tr>
<td>T1b</td>
</tr>
<tr>
<td>T1c</td>
</tr>
<tr>
<td>T2a</td>
</tr>
<tr>
<td>T2b</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T4</td>
</tr>
</tbody>
</table>

### Form Question: Vascular invasion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>V0: None</td>
</tr>
<tr>
<td>V1: Microscopic</td>
</tr>
<tr>
<td>V2: Macroscopic</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Form Question: Status of the fissures

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjacent lobe invaded</td>
</tr>
<tr>
<td>Adjacent lobe not invaded</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Form Question: Lymphatic vessel invasion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ly0: No invasion</td>
</tr>
<tr>
<td>Ly1: Invasion</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>
Form Question: Pleural lavage cytology

<table>
<thead>
<tr>
<th>Display Value</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>Not done</td>
<td></td>
</tr>
<tr>
<td>No Data</td>
<td></td>
</tr>
</tbody>
</table>

Form Question: Perineural invasion

<table>
<thead>
<tr>
<th>Display Value</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

Form Question: Histology of separate nodules confirmed?

<table>
<thead>
<tr>
<th>Display Value</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

Form Question: Spread through the air spaces (STAS)

<table>
<thead>
<tr>
<th>Display Value</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>Not evaluated</td>
<td></td>
</tr>
</tbody>
</table>
1.12 Post Surgical/Pathologic N Category

### Subject ID: 200100001
### Site Number: University of Michigan
### Principle Investigator: Smith, John
### Patient Code: UMC045-13

**IMPORTANT:** This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

**TAB:** Nodal Staging

**Instructions:** Indicate nodal sampling results at each station based on pathology review of attempted resection of the primary tumor.

**Key to nodal station results:**
- *: At least one node examined in this region was considered to be metastatic.
- #: All nodes examined in this region were considered to be nonmetastatic.
- ND: No node examination done in this region or results were equivocal (none considered metastatic).

**Location of primary tumour (with highest T-category):** Fill out from Primary Tumour Description form where VISITNO = "1".

#### N Category:

**Supraclavicular**
- #1R:  
- #1L:  

**Upper para-tracheal**
- #2R:  
- #2L:  

**Pre-vascular**
- #3aR:  
- #3aL:  

**Retractracheal**
- #3p:  

**Lower para-tracheal**
- #4R:  
- #4L:  

**Sub-aortic**
- #6:  

**Para-aortic**
- #6:  

**Subcarinal**
- #7:  

**Paraoesophageal**
- #8R:  
- #8L:  

**Pulmonary ligament**
- #9R:  
- #9L:  

The International Association for the Study of Lung Cancer (IASLC)
Lung Cancer Staging Project, Data Elements v1.13, 10JAN2021

Hilar
#10R: □ □ □ #10L: □ □ □

Interlobar
#11R: □ □ □ #11L: □ □ □

Lobar
#12R: □ □ □ #12L: □ □ □

Segmental
#13R: □ □ □ #13L: □ □ □

Subsegmental
#14R: □ □ □ #14L: □ □ □

Size of largest node: □□□□ cm

Direct nodal invasion from tumour? □ □ □

Direct invasion of N3 nodes: □ □ □

Direct invasion of N2 nodes: □ □ □

Direct invasion of N1 nodes: □ □ □

Extracapsular involvement? □ □ □

If 'Yes', N3 extracapsular involvement: □ □ □

If 'Yes', N2 extracapsular involvement: □ □ □

If 'Yes', N1 extracapsular involvement: □ □ □

Number of N3 nodes removed: □□□□ Number of positive N3 nodes: □□□□

Number of N2 nodes removed: □□□□ Number of positive N2 nodes: □□□□

Number of N1 nodes removed: □□□□ Number of positive N1 nodes: □□□□

Submit □ □ □ Cancel □ □ □ eCRF Version: 1.1
**The International Association for the Study of Lung Cancer (IASLC)**

**Lung Cancer Staging Project, Data Elements v1.13, 10JAN2021**

**Form Question: 'N Category'**

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N0</td>
</tr>
<tr>
<td>N1</td>
</tr>
<tr>
<td>N2</td>
</tr>
<tr>
<td>N3</td>
</tr>
<tr>
<td>NX</td>
</tr>
</tbody>
</table>

**Form Question: All staging questions excluding the ‘N Category’ question and the ‘Direct nodal invasion from tumour?’ and ‘Extracapsular involvement?’ questions**

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
</tr>
<tr>
<td>-</td>
</tr>
<tr>
<td>ND</td>
</tr>
</tbody>
</table>

**Form Question: ‘Direct nodal invasion from tumour?’ and ‘Extracapsular involvement?’ questions**

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>
1.13 M-Descriptors, After Attempted Resection of the Primary Tumour

<table>
<thead>
<tr>
<th>Subject ID: 20010001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Number: University of Michigan</td>
</tr>
<tr>
<td>Principle Investigator: Smith, John</td>
</tr>
<tr>
<td>Patient Code: UM045-13</td>
</tr>
</tbody>
</table>

**IMPORTANT:** This form has a 30 minute timeout period. You can click or type on the form at any time to reset your timeout period.

**TAB: M descriptors**

**Instructions:** Indicate M-category. [Click here for 8th edition criteria]

Only new sites of disease, discovered during surgery or post-surgical staging, should be indicated on this form.

**M Category Before Attempted Resection of the Primary Tumour:** <prefilled>

**M Category After Attempted Resection of the Primary Tumour:**

- Pleural nodules:
- Pericardial nodules:
- Pleural effusion:
  - Cytology:
- Pericardial effusion:
  - Cytology:
- Contralateral lung metastasis:

**Were there any additional sites of metastasis that were identified during surgery or post-surgical staging?**

<table>
<thead>
<tr>
<th>Sites of distant metastases</th>
<th>Presence/Number of Lesions</th>
<th>If multiple lesions, specify number of lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal lymph nodes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other distant lymph nodes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peritoneum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[Submit] [Cancel] [eCRF Version: 1.0]
The International Association for the Study of Lung Cancer (IASLC)
Lung Cancer Staging Project, Data Elements v1.13, 10JAN2021

**Form Question:** M Category Before Attempted Resection of Primary Tumour; M Category After Attempted Resection of Primary Tumour

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
</tr>
<tr>
<td>M1a</td>
</tr>
<tr>
<td>M1b</td>
</tr>
<tr>
<td>M1c</td>
</tr>
</tbody>
</table>

**Form Question:** Pleural nodules; Pleural effusion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
</tr>
<tr>
<td>Ipsilateral</td>
</tr>
<tr>
<td>Contralateral</td>
</tr>
<tr>
<td>Bilateral</td>
</tr>
<tr>
<td>Present, side not specified</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Form Question:** Pericardial nodules; Pericardial effusion

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Form Question:** Cytology

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
</tr>
<tr>
<td>Negative</td>
</tr>
<tr>
<td>Not done</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Form Question:** Were there any additional sites of metastasis that were identified during surgery or post-surgical staging?

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>
Form Question: Sites of distant metastases

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single lesion</td>
</tr>
<tr>
<td>Multiple lesions</td>
</tr>
<tr>
<td>Present, number of lesion not specified</td>
</tr>
<tr>
<td>Absent</td>
</tr>
</tbody>
</table>
1.14 Systemic Treatments and Radiotherapy

Form Question: Line of Treatment

<table>
<thead>
<tr>
<th>Display Value</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>First line</td>
<td></td>
</tr>
<tr>
<td>Second line</td>
<td></td>
</tr>
<tr>
<td>Third line or more</td>
<td></td>
</tr>
<tr>
<td>Neoadjuvant</td>
<td></td>
</tr>
<tr>
<td>Adjuvant</td>
<td></td>
</tr>
</tbody>
</table>
**Form Question:** Therapy

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afatinib</td>
</tr>
<tr>
<td>Alectinib</td>
</tr>
<tr>
<td>Atezolizumab</td>
</tr>
<tr>
<td>Avelumab</td>
</tr>
<tr>
<td>Bevacizumab</td>
</tr>
<tr>
<td>Brigatinib</td>
</tr>
<tr>
<td>Cabozantinib</td>
</tr>
<tr>
<td>Carboplatin</td>
</tr>
<tr>
<td>Ceritinib</td>
</tr>
<tr>
<td>Cetuximab</td>
</tr>
<tr>
<td>Cisplatin</td>
</tr>
<tr>
<td>Crizotinib</td>
</tr>
<tr>
<td>Dabrafenib</td>
</tr>
<tr>
<td>Dacomitinib</td>
</tr>
<tr>
<td>Docetaxel</td>
</tr>
<tr>
<td>Durvalumab</td>
</tr>
<tr>
<td>Entrectinib</td>
</tr>
<tr>
<td>Erlotinib</td>
</tr>
<tr>
<td>Etoposide</td>
</tr>
<tr>
<td>Gefitinib</td>
</tr>
<tr>
<td>Gemcitabine</td>
</tr>
<tr>
<td>Hycamitin</td>
</tr>
<tr>
<td>Intedanib</td>
</tr>
<tr>
<td>Lorlatinib</td>
</tr>
<tr>
<td>LOXO 101</td>
</tr>
<tr>
<td>LOXO 292</td>
</tr>
<tr>
<td>Necitumumab</td>
</tr>
<tr>
<td>Nedaplatin</td>
</tr>
<tr>
<td>Nintedanib</td>
</tr>
<tr>
<td>Nivolumab</td>
</tr>
<tr>
<td>Octreotide</td>
</tr>
<tr>
<td>Osimertinib</td>
</tr>
<tr>
<td>Paclitaxel</td>
</tr>
<tr>
<td>Pembrolizumab</td>
</tr>
<tr>
<td>Pemetrexed</td>
</tr>
<tr>
<td>Ponatinib</td>
</tr>
<tr>
<td>Radiation: Definitive</td>
</tr>
<tr>
<td>Radiation: Palliative</td>
</tr>
<tr>
<td>Radiation: Stereotactic</td>
</tr>
<tr>
<td>Ramicirumab</td>
</tr>
<tr>
<td>Trametinib</td>
</tr>
<tr>
<td>Vemurafenib</td>
</tr>
<tr>
<td>Vinblastine</td>
</tr>
<tr>
<td>Vinorelbine</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>
1.15 Follow-up

**Form Question:** Cause of Death, if Deceased

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death due to lung cancer – locoregional relapse</td>
</tr>
<tr>
<td>Death due to lung cancer – distant relapse</td>
</tr>
<tr>
<td>Death due to lung cancer – locoregional and distant relapse</td>
</tr>
<tr>
<td>Death due to lung cancer – Not otherwise specified</td>
</tr>
<tr>
<td>Death due to second primary cancer</td>
</tr>
<tr>
<td>Death, non-cancer cause</td>
</tr>
<tr>
<td>Cause of death unknown</td>
</tr>
</tbody>
</table>
1.16 Progression/Recurrence

Subject ID: 20010001
Site Number: University of Michigan
Principle Investigator: Smith, John
Patient Code: UM045-13

IMPORTANT: This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

If the patient’s disease progressed or recurred after first-line or neoadjuvant treatment, please document the date of progression or recurrence below. Note: This date only refers to the first progression or recurrence of the newly diagnosed lung cancer. At this time, the Staging and Prognostic Factors Committee is not collecting diagnostic dates of second cancers of any kind.

Date of progression or recurrence: □ □ - □ □ - □ □ (dd-mm-yyyy)

[Submit]  [Cancel]  eCRF Version: 1.0
1.17 Genetic Biomarkers

Subject ID: 2010001
Site Number: University of Michigan
Principal Investigator: Smith, John
Patient Code: UIM4513

IMPORTANT: This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

Section 1. Submit the date, type of sample, and each platform/panel requested.
For each genetic assessment other than IHC or mass spectrometry, please document the date, type of sample, and platform/panel below. Do not select platform/panels marked as "obsolete." If your platform/panel does not appear in the list below, contact webhelpiaslc@crab.org so that we can add your platform/panel to the dropdown menu, or if appropriate, we will instead help you create a customized platform/panel. You will be asked to provide information about the genetic features tested in your platform/panel before it can be added.

Date of sample: [ ] - [ ] - [ ] (dd-mm-yyyy)

Please choose a platform/panel, or a customized platform/panel, but do not choose both.

Type of Sample: Platform/Panel: Or Customized platform/panel

Total mutation burden: [ ] (mutations per Megabase)

Were any results positive or inconclusive for genetic abnormalities? ○ Yes. Complete section 2 below.
○ No. Skip section 2 and click the "Add" button (exception: do not skip section 2 for single allele-specific tests).

Section 2. Submit any point mutations, small intragenic (within gene) deletions, and fusions that were detected using Sanger, PCR or NGS.
- If a commercial multigene NGS platform/panel was used, as you have worked with us to document your custom panel, then you only need to report the positive and inconclusive results in this section. Use the "Add" button to submit each positive or inconclusive result if all results on the panel were negative, you can leave Section 2 blank.
- If multiple, single allele-specific tests were used (such as Sanger or PCR), report all positive, negative, and inconclusive test results. Use the "Add" button to submit each positive, negative, or inconclusive result.
- Generally, only genes that carry mutations in >1% of NSCLC patients in the GENIE Consortium are included below. Rare mutations in genes that do not appear below do not need to be reported. However, if a specific gene of interest does not appear, please contact us at webhelpiaslc@crab.org.
- Once Section 1 is complete, continue to the Protein Aberrations form to report protein expression testing conducted with IHC, mass spectrometry, etc.
- Once Section 1 is complete, continue to the Copy Number Alterations form to report copy number amplifications, and large deletions detected using NGS, FISH, or CISH. If all CNAs tested were negative, then you only need to document the tests above in Section 1, and do not need to complete the CNA form.

Gene: DNA Variant (if applicable): Other variant, specify: Genetic abnormality:

Add Cancel

Genetic Biomarkers for this Subject
To view complete information for a record, or to edit or delete an record, click on the entry in the Gene column:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sample Date</th>
<th>Sample Type</th>
<th>Platform</th>
<th>Custom Platform</th>
<th>Total Mutation</th>
<th>Pos/Incon?</th>
<th>DNA Variant</th>
<th>Other Variant</th>
<th>Gene Aberrm.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK</td>
<td>12-JUN-2017</td>
<td>Biopsy</td>
<td>Sanger</td>
<td>Hospital A Panel</td>
<td>N</td>
<td>ALK Fusiform</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Return to Subject Info eCRF Version: 1.1
The International Association for the Study of Lung Cancer (IASLC)
Lung Cancer Staging Project, Data Elements v1.13, 10JAN2021

Form Question: Gene
Display Value:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABL1</td>
<td>CREBBP</td>
</tr>
<tr>
<td>AMER1</td>
<td>CSF1R</td>
</tr>
<tr>
<td>APC</td>
<td>CTNNB1</td>
</tr>
<tr>
<td>AR</td>
<td>CUX1</td>
</tr>
<tr>
<td>ARAF</td>
<td>DICER1</td>
</tr>
<tr>
<td>ARID1A</td>
<td>DIS3</td>
</tr>
<tr>
<td>ARID1B</td>
<td>DMD</td>
</tr>
<tr>
<td>ARID2</td>
<td>DNMT3A</td>
</tr>
<tr>
<td>ASXL1</td>
<td>EML4</td>
</tr>
<tr>
<td>ATM</td>
<td>EP300</td>
</tr>
<tr>
<td>ATR</td>
<td>EPHA3</td>
</tr>
<tr>
<td>ATRX</td>
<td>EPHA5</td>
</tr>
<tr>
<td>AXL</td>
<td>EPHA7</td>
</tr>
<tr>
<td>BAP1</td>
<td>EPHB1</td>
</tr>
<tr>
<td>BCORL1</td>
<td>ERBB4</td>
</tr>
<tr>
<td>BLM</td>
<td>ERCC2</td>
</tr>
<tr>
<td>BRCA1</td>
<td>ERCC3</td>
</tr>
<tr>
<td>BRCA2</td>
<td>ERCC4</td>
</tr>
<tr>
<td>BRIP1</td>
<td>ERCC5</td>
</tr>
<tr>
<td>CARD11</td>
<td>ESR1</td>
</tr>
<tr>
<td>CBL</td>
<td>ETV1</td>
</tr>
<tr>
<td>CD74NRG1</td>
<td>FANCA</td>
</tr>
<tr>
<td>CDC73</td>
<td>FAT1</td>
</tr>
<tr>
<td>CDH1</td>
<td>FBXW7</td>
</tr>
<tr>
<td>CDKN2A</td>
<td>FLT1</td>
</tr>
<tr>
<td>CIITA</td>
<td>FLT3</td>
</tr>
<tr>
<td>AMER1</td>
<td>CREBBP</td>
</tr>
<tr>
<td>APC</td>
<td>CTNNB1</td>
</tr>
<tr>
<td>AR</td>
<td>CUX1</td>
</tr>
<tr>
<td>ARAF</td>
<td>DICER1</td>
</tr>
<tr>
<td>ARID1A</td>
<td>DIS3</td>
</tr>
<tr>
<td>ARID1B</td>
<td>DMD</td>
</tr>
<tr>
<td>ARID2</td>
<td>DNMT3A</td>
</tr>
<tr>
<td>ASXL1</td>
<td>EML4</td>
</tr>
<tr>
<td>ATM</td>
<td>EP300</td>
</tr>
<tr>
<td>ATR</td>
<td>EPHA3</td>
</tr>
<tr>
<td>ATRX</td>
<td>EPHA5</td>
</tr>
<tr>
<td>AXL</td>
<td>EPHA7</td>
</tr>
<tr>
<td>BAP1</td>
<td>EPHB1</td>
</tr>
<tr>
<td>BCORL1</td>
<td>ERBB4</td>
</tr>
<tr>
<td>BLM</td>
<td>ERCC2</td>
</tr>
<tr>
<td>BRCA1</td>
<td>ERCC3</td>
</tr>
<tr>
<td>BRCA2</td>
<td>ERCC4</td>
</tr>
<tr>
<td>BRIP1</td>
<td>ERCC5</td>
</tr>
<tr>
<td>CARD11</td>
<td>ESR1</td>
</tr>
<tr>
<td>CBL</td>
<td>ETV1</td>
</tr>
<tr>
<td>CD74NRG1</td>
<td>FANCA</td>
</tr>
<tr>
<td>CDC73</td>
<td>FAT1</td>
</tr>
<tr>
<td>CDH1</td>
<td>FBXW7</td>
</tr>
<tr>
<td>CDKN2A</td>
<td>FLT1</td>
</tr>
<tr>
<td>CIITA</td>
<td>FLT3</td>
</tr>
</tbody>
</table>

Form Question: Type of Sample

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Cytology</td>
</tr>
<tr>
<td>Plasma</td>
</tr>
</tbody>
</table>
Form Question: Platform/Panel

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanger (obsolete)</td>
</tr>
<tr>
<td>Sanger: EGFR Point Mutations</td>
</tr>
<tr>
<td>Sanger: BRAF Point Mutations</td>
</tr>
<tr>
<td>Sanger: HER2 (ERBB2) Point Mutations</td>
</tr>
<tr>
<td>Sanger: KRAS Point Mutations</td>
</tr>
<tr>
<td>NGS (obsolete)</td>
</tr>
<tr>
<td>COBAS EGFR Mutation Test v2</td>
</tr>
<tr>
<td>NGS: Oncomine (obsolete)</td>
</tr>
<tr>
<td>NGS: ThermoFisher Ion Ampliseq v2</td>
</tr>
<tr>
<td>NGS: Oncomine Dx Target Test</td>
</tr>
<tr>
<td>NGS: Oncomine Lung cfDNA Assay</td>
</tr>
<tr>
<td>NGS: Oncomine Focus</td>
</tr>
<tr>
<td>NGS: Oncomine Solid Tumor Fusion</td>
</tr>
<tr>
<td>NGS: OncoGenBasic S1 Panel (BRAF, KRAS, NRAS, EGFR)</td>
</tr>
<tr>
<td>NGS: OncoGenBasic S2 Panel (AKT1, PIK3CA)</td>
</tr>
<tr>
<td>NGS: Guardant360</td>
</tr>
<tr>
<td>NGS: MSK-IMPACT</td>
</tr>
<tr>
<td>NGS: FoundationOne</td>
</tr>
<tr>
<td>NGS: FoundationOne CDX</td>
</tr>
<tr>
<td>NGS: Geneseeq Pan-Genomic (425 cancer genes)</td>
</tr>
<tr>
<td>NGS: Geneseeq Pulmocan (139 lung cancer genes)</td>
</tr>
<tr>
<td>NGS: Geneseeq Tetradeqan (14 NCCN lung cancer genes)</td>
</tr>
<tr>
<td>NGS: Caris MI Profile</td>
</tr>
<tr>
<td>NGS: Caris MI Tumor Seek</td>
</tr>
<tr>
<td>NGS: NeoGenomics Lung NGS Fusion Profile</td>
</tr>
<tr>
<td>NGS: NeoGenomics NeoTYPE Lung Tumor Profile</td>
</tr>
<tr>
<td>NGS: Tempus xT</td>
</tr>
<tr>
<td>NGS: Tempus xF</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Pan-Cancer Cell-Free Assay</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Comprehensive Assay v1</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Comprehensive Assay v3</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Tumor Mutation Load Assay</td>
</tr>
<tr>
<td>NGS: Illumina TruSight(tm) Oncology 500</td>
</tr>
<tr>
<td>ddPCR: Biodesix Lung Reflex genestrat</td>
</tr>
<tr>
<td>qPCR (obsolete)</td>
</tr>
<tr>
<td>RT-qPCR (obsolete)</td>
</tr>
<tr>
<td>qPCR/RT-qPCR/ddPCR: EGFR Point Mutations</td>
</tr>
<tr>
<td>qPCR/RT-qPCR/ddPCR: BRAF Point Mutations</td>
</tr>
<tr>
<td>qPCR/RT-qPCR/ddPCR: HER2 (ERBB2) Point Mutations</td>
</tr>
<tr>
<td>qPCR/RT-qPCR/ddPCR: KRAS Point Mutations</td>
</tr>
<tr>
<td>RT-PCR Biocartis Idylla: EGFR Point Mutations</td>
</tr>
<tr>
<td>RT-PCR Biocartis Idylla: BRAF Point Mutations</td>
</tr>
<tr>
<td>RT-PCR Biocartis Idylla: KRAS Point Mutations</td>
</tr>
<tr>
<td>RT-PCR Biocartis Idylla: NRAS-BRAF Point Mutations</td>
</tr>
<tr>
<td>FISH (obsolete)</td>
</tr>
<tr>
<td>Test Description</td>
</tr>
<tr>
<td>----------------------------------</td>
</tr>
<tr>
<td>FISH: ALK Fusion</td>
</tr>
<tr>
<td>FISH: ROS1 Fusion</td>
</tr>
<tr>
<td>FISH: MET Amplifications</td>
</tr>
<tr>
<td>FISH: RET Fusion</td>
</tr>
<tr>
<td>CISH: ALK Fusion</td>
</tr>
<tr>
<td>CISH: ROS1 Fusion</td>
</tr>
<tr>
<td>CISH: MET Amplifications</td>
</tr>
<tr>
<td>CISH: RET Fusion</td>
</tr>
<tr>
<td>Other (obsolete)</td>
</tr>
<tr>
<td>aCGH (array comparative genomic hybridisation)</td>
</tr>
<tr>
<td>SNP array: Affymetrix 500K array</td>
</tr>
<tr>
<td>SNP array: Affymetrix 5.0 SNP array</td>
</tr>
<tr>
<td>SNP array: Affymetrix 6.0 SNP array</td>
</tr>
<tr>
<td>SNP array: OncoScan CNV Plus Assay</td>
</tr>
</tbody>
</table>

**Form Question:** Were any results positive or inconclusive for genetic abnormalities?

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes. Complete section 2 below</td>
</tr>
<tr>
<td>No Skip section 2* and click the &quot;Add&quot; button (*exception: do not skip section 2 for single allele-specific tests).</td>
</tr>
</tbody>
</table>

**Form Question:** Genetic abnormality

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Inconclusive</td>
</tr>
</tbody>
</table>
1.18 Copy Number Alteration (CAN) Biomarkers

Subject ID: 20210001
Site Number: University of Michigan
Principal Investigator: Smith, John
Patient Code: UM08-13

IMPORTANT: This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

Report all copy number alterations detected by NGS, FISH, or CISH.
- Report all amplifications / duplications, and large deletions tested.
- If a commercial NGS platform/panel was used, or you have worked with us to document your custom panel, please report each abnormal and inconclusive CAN result in this section.
- If multiple, single tests were used (such as FISH or CISH), please report each abnormal, and inconclusive result.
- Use the "Add" button to submit each result.
- If all CANs tested were negative, you do not need to complete this section, provided that the test used was already reported on the GenoX Biomarkers form.

Date of sample: [ ] - [ ] - [ ] (dd-mm-yyyy)

Please choose a platform/panel, or a customized platform/panel, but do not choose both.

Type of Sample: Platform/Panel: Or Customized platform/panel

If specific CAN does not appear on the list, please contact us at webhelp@iaslc.org

Copy Number Alteration: Average Gene Copy Number: Genotype: Average Gene Centromere Ratio: Centromere Copy Number:

CNA Biomarkers for this Subject
To view complete information for a record, or to edit or delete an record, click on the entry in the CAN column.

CNA: Data Assessed: Type of Sample: Platform: Custom Platform: CNA Result: Average Gene Copy Number: Genotype: Average Gene Centromere Ratio: Centromere Copy Number:


[Add] [Cancel]
### Display Value

<table>
<thead>
<tr>
<th>Copy Number Alteration</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR amplification</td>
</tr>
<tr>
<td>BRAF amplification</td>
</tr>
<tr>
<td>CCND1 11q13 AMP</td>
</tr>
<tr>
<td>CCND2 amplification</td>
</tr>
<tr>
<td>CCNE1 19q12 AMP</td>
</tr>
<tr>
<td>CDK4 12q14 AMP</td>
</tr>
<tr>
<td>CDK6 amplification</td>
</tr>
<tr>
<td>CDKN2A 9p21 DEL</td>
</tr>
<tr>
<td>CDKN2B 9p21 DEL</td>
</tr>
<tr>
<td>CEBPA 19q13.1 AMP</td>
</tr>
<tr>
<td>EGFR 7p12 AMP</td>
</tr>
<tr>
<td>ERBB2 17q12 AMP</td>
</tr>
<tr>
<td>ETV1 7p21.3 AMP</td>
</tr>
<tr>
<td>FGFR1 11q13.1 AMP</td>
</tr>
<tr>
<td>FGFR1 Amplification</td>
</tr>
<tr>
<td>FGFR2 Amplification</td>
</tr>
<tr>
<td>FGFR3 Amplification</td>
</tr>
<tr>
<td>FGFR4 Amplification</td>
</tr>
<tr>
<td>FOXA1 14q21.1 AMP</td>
</tr>
<tr>
<td>KIT amplification</td>
</tr>
<tr>
<td>KRAS 12p12.1 AMP</td>
</tr>
<tr>
<td>MCL1 1q21 AMP</td>
</tr>
<tr>
<td>MDM2 12q14.3-q15 AMP</td>
</tr>
<tr>
<td>MET 7q31 AMP</td>
</tr>
<tr>
<td>MYC 8q24.21 AMP</td>
</tr>
<tr>
<td>NFKBIA 14q13 AMP</td>
</tr>
<tr>
<td>NKX2-1 14q13 AMP</td>
</tr>
<tr>
<td>PDGFRA amplification</td>
</tr>
<tr>
<td>PIK3CA 3q26.3 AMP</td>
</tr>
<tr>
<td>PTEN 10q23.3 DEL</td>
</tr>
<tr>
<td>RAF1 amplification</td>
</tr>
<tr>
<td>RECQL4 8q24.3 AMP</td>
</tr>
<tr>
<td>RICTOR AMP</td>
</tr>
</tbody>
</table>

### Form Question: Type of Sample

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Cytology</td>
</tr>
<tr>
<td>Plasma</td>
</tr>
</tbody>
</table>
### Form Question: Platform

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FISH (obsolete)</td>
</tr>
<tr>
<td>FISH: MET Amplifications</td>
</tr>
<tr>
<td>NGS (obsolete)</td>
</tr>
<tr>
<td>NGS: ThermoFisher Ion Ampliseq v2</td>
</tr>
<tr>
<td>NGS: Oncomine Dx Target Test</td>
</tr>
<tr>
<td>NGS: Oncomine Lung cfDNA Assay</td>
</tr>
<tr>
<td>NGS: Oncomine Focus</td>
</tr>
<tr>
<td>NGS: Oncomine Solid Tumor Fusion</td>
</tr>
<tr>
<td>NGS: OncoGenBasic S1 Panel (BRAF, KRAS, NRAS, EGFR)</td>
</tr>
<tr>
<td>NGS: OncoGenBasic S2 Panel (AKT1, PIK3CA)</td>
</tr>
<tr>
<td>NGS: Guardant360</td>
</tr>
<tr>
<td>NGS: MSK-IMPACT</td>
</tr>
<tr>
<td>NGS: FoundationOne CDX</td>
</tr>
<tr>
<td>NGS: Geneseeq Pan-Genomic (425 cancer genes)</td>
</tr>
<tr>
<td>NGS: Geneseeq Pulmocan (139 lung cancer genes)</td>
</tr>
<tr>
<td>NGS: Geneseeq Tetradecan (14 NCCN lung cancer genes)</td>
</tr>
<tr>
<td>NGS: Caris MI Profile</td>
</tr>
<tr>
<td>NGS: Caris MI Tumor Seek</td>
</tr>
<tr>
<td>NGS: NeoGenomics Lung NGS Fusion Profile</td>
</tr>
<tr>
<td>NGS: NeoGenomics NeoTYPE Lung Tumor Profile</td>
</tr>
<tr>
<td>NGS: Tempus xT</td>
</tr>
<tr>
<td>NGS: Tempus xF</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Pan-Cancer Cell-Free Assay</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Comprehensive Assay v1</td>
</tr>
<tr>
<td>NGS: ThermoFisher Oncomine Comprehensive Assay v3</td>
</tr>
<tr>
<td>NGS: Illumina TruSight(tm) Oncology 500</td>
</tr>
<tr>
<td>CISH (obsolete)</td>
</tr>
<tr>
<td>OncoScan (obsolete)</td>
</tr>
<tr>
<td>CISH: MET Amplifications</td>
</tr>
<tr>
<td>aCGH (Array comparative genomic hybridisation)</td>
</tr>
<tr>
<td>SNP array: Affymetrix 500K array</td>
</tr>
<tr>
<td>SNP array: Affymetrix 5.0 SNP array</td>
</tr>
<tr>
<td>SNP array: Affymetrix 6.0 SNP array</td>
</tr>
<tr>
<td>SNP array: OncoScan CNV Plus Assay</td>
</tr>
<tr>
<td>NanoString nCounter: Vantage 3D DNA:Fusion:Protein Lung Assay</td>
</tr>
<tr>
<td>NanoString nCounter: Vantage 3D Lung Fusion Panel</td>
</tr>
</tbody>
</table>

### Form Question: Genotype

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homozygous</td>
</tr>
<tr>
<td>Heterozygous</td>
</tr>
</tbody>
</table>

### Form Question: CNA Result

<table>
<thead>
<tr>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>Abnormal</td>
</tr>
<tr>
<td>Inconclusive</td>
</tr>
</tbody>
</table>
1.19 Protein Alterations

Subject ID: 20010001
Site Number: University of Michigan
Principal Investigator: Smith, John
Patient Code: UM045-13

IMPORTANT: This form has a 20 minute timeout period. You can click or type on the form at any time to reset your timeout period.

Report all protein expression testing conducted with IHC, spectrometry, etc
- For each protein, at a minimum please provide the date, sample, platform, protein, and expression result (% tumor cells, positive/negative/indeterminate, or H-score).
- Please report all results even if they were negative or inconclusive.
- Use the “Add” button to submit each expression result.

Date of sample: __________ - __________ - ________ (dd-mmm-yyyy)

Type of Sample: __________
Platform: __________
Antibody: __________

If specific protein does not appear on the list, please contact us at webhelpiaslc@crab.org

Protein: __________
% Tumor cells: __________
Expression: __________
% Immune cells: __________
H-Score: __________

Add Cancel

Protein Alterations for this Subject
To view complete information for a record, or to edit or delete an record, click on the entry in the Protein column.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Date Assessed</th>
<th>Type of Sample</th>
<th>Platform</th>
<th>Antibody</th>
<th>% Tumor cells</th>
<th>Expression</th>
<th>% Immune cells</th>
<th>H-Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-L1</td>
<td>12-JUN-2017</td>
<td>Biopsy</td>
<td>IHC</td>
<td>IHC</td>
<td>36</td>
<td>Positive</td>
<td>45</td>
<td>121</td>
</tr>
<tr>
<td>PD-L1</td>
<td>16-JUN-2017</td>
<td>Cytology</td>
<td>Mass spectrometry</td>
<td>32</td>
<td>Negative</td>
<td>42</td>
<td>181</td>
<td></td>
</tr>
</tbody>
</table>

Return to Subject Info

eCRF Version: 1.2
<table>
<thead>
<tr>
<th>Form Question: Platform</th>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IHC</td>
</tr>
<tr>
<td></td>
<td>Mass spectrometry</td>
</tr>
<tr>
<td></td>
<td>ELISA</td>
</tr>
<tr>
<td></td>
<td>Luminex</td>
</tr>
<tr>
<td></td>
<td>NanoString nCounter: Vantage 3D</td>
</tr>
<tr>
<td></td>
<td>DNA:Fusion:Protein Lung Assay</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Form Question: Expression</th>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>Inconclusive</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Form Question: Antibody</th>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BioCare 4A4</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling 43B2 (L858R Mutant Specific)</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling D4D6</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling D5F3</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling D6B6 (E746-A750del Specific)</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling E1L3N</td>
</tr>
<tr>
<td></td>
<td>DAKO 22-C3</td>
</tr>
<tr>
<td></td>
<td>DAKO 28-8</td>
</tr>
<tr>
<td></td>
<td>DAKO 73-10</td>
</tr>
<tr>
<td></td>
<td>Dako ALK1</td>
</tr>
<tr>
<td></td>
<td>Dako OV-TL</td>
</tr>
<tr>
<td></td>
<td>Novocastra/Abcam/Leica/Novus 5A4</td>
</tr>
<tr>
<td></td>
<td>Thermo Fisher/Abcam 5A4</td>
</tr>
<tr>
<td></td>
<td>Ventana D5F3 CDx</td>
</tr>
<tr>
<td></td>
<td>Ventana SP141</td>
</tr>
<tr>
<td></td>
<td>Ventana SP142</td>
</tr>
<tr>
<td></td>
<td>Ventana SP263</td>
</tr>
<tr>
<td></td>
<td>Ventana SP384</td>
</tr>
<tr>
<td></td>
<td>Ventana/SP44</td>
</tr>
<tr>
<td></td>
<td>Ventana 4A4</td>
</tr>
<tr>
<td></td>
<td>Ventana 8G7G3/1</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Form Question: Protein</th>
<th>Display Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-L1</td>
<td>DAKO 28-8</td>
</tr>
<tr>
<td></td>
<td>DAKO 22-C3</td>
</tr>
<tr>
<td></td>
<td>DAKO 73-10</td>
</tr>
<tr>
<td></td>
<td>Ventana SP142</td>
</tr>
<tr>
<td></td>
<td>Ventana SP263</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling E1L3N</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>ALK</td>
<td>DAKo ALK1</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling D5F3</td>
</tr>
<tr>
<td></td>
<td>Ventana D5F3 CDx</td>
</tr>
<tr>
<td></td>
<td>Novocastra/Abcam/Leica/Novus 5A4</td>
</tr>
<tr>
<td></td>
<td>Thermo Fisher/Abcam 5A4</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>ROS</td>
<td>Cell Signaling D4D6</td>
</tr>
<tr>
<td></td>
<td>Ventana SP384</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>EGFR</td>
<td>Cell Signaling 43B2 (L858R Mutant Specific)</td>
</tr>
<tr>
<td></td>
<td>Cell Signaling D6B6 (E746-A750del Specific)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>MET</td>
<td>Ventana/SP44</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>P63</td>
<td>BioCare 4A4</td>
</tr>
<tr>
<td></td>
<td>Ventana 4A4</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CK7</td>
<td>Dako OV-TL</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>TTF1</td>
<td>Ventana SP141</td>
</tr>
<tr>
<td></td>
<td>Ventana 8G7G3/1</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>